Treatment studies for localized, muscle invasive bladder cancer (MIBC) aim to establish a treatment that can be used to achieve a high rate of local tumor control. This would allow many patients to avoid surgical removal of the bladder or extended radiotherapy, which would significantly improve their quality of life. In the SAKK 06/19 trial, the standard treatment for localized MIBC will be supplemented with Bacillus Calmette Guérin (BCG) and atezolizumab.
46 patients with localized MIBC will take part in the trial, all of whom will receive the trial therapy.
For more information on where and how this trial is conducted, consult the trial website.